Dr. Ioana-Miruna Stanciu | Carol Davila University of Medicine and Pharmacy | Romania
Dr. Ioana-Miruna Stanciu 🎗️ is a dedicated medical oncologist and researcher based in Bucharest, Romania. She is an Assistant Lecturer at Carol Davila University of Medicine and Pharmacy and a Ph.D. candidate in Medical Oncology. With a passion for cancer treatment and translational research, she actively participates in clinical trials, supervises medical students, and presents at international oncology conferences. She is a member of prestigious oncology societies, including ESMO and ASCO. Her expertise spans immunotherapy, breast cancer, and precision medicine, contributing to advancements in oncology care and education. 🏥🔬🎤
Professional Profile:
ORCID
SCOPUS
Google Scholar
Suitability for Best Researcher Award
Dr. Ioana-Miruna Stanciu is a highly suitable candidate for the Best Researcher Award due to her significant contributions to oncology research, clinical trials, and education. As a Ph.D. candidate and Assistant Lecturer, she actively advances immunotherapy, breast cancer, and precision medicine. Her involvement in clinical trials, international oncology conferences, and prestigious societies like ESMO and ASCO highlights her global impact. Her dedication to translational research, patient care, and mentoring future oncologists makes her a deserving recipient of this recognition.
Education & Experience
- 🎓 Ph.D. in Medical Oncology – Carol Davila University of Medicine and Pharmacy, Bucharest (2021 – present)
- 🎓 Bachelor’s Degree in Medicine – Carol Davila University of Medicine and Pharmacy, Bucharest (2014 – 2020)
- 🎓 High School Degree – National College “Mihai Viteazul,” Bucharest (2010 – 2014)
- 👩🏫 Assistant Lecturer in Medical Oncology – Carol Davila University of Medicine and Pharmacy, Bucharest (2022 – present)
- 🏨 Resident in Medical Oncology – Elias University Emergency Hospital (2021 – present)
- 🧑🎓 Study Coordinator – AMGEN 20230016 Clinical Trial (2024)
- 📑 Supervisor of 16 Bachelor’s Theses – September 2024 session
Professional Development
Dr. Ioana-Miruna Stanciu 🏥 has actively engaged in numerous oncology conferences, workshops, and research initiatives to enhance her expertise. She has attended global medical congresses such as ESMO, ASCO, and ROSPEN, presenting clinical cases and research findings on breast cancer, immunotherapy, and precision oncology. As a lecturer, she has contributed to oncology education, guiding students and professionals in advanced cancer treatments. Additionally, she plays a key role in clinical trials, helping to develop new therapeutic strategies. Through continuous learning and collaboration, she aims to improve cancer care and patient outcomes. 🎤🔬📖
Research Focus
Dr. Stanciu’s research primarily focuses on medical oncology and immunotherapy, particularly in breast cancer, lung cancer, and systemic therapies. 🎗️ She investigates the safety and efficacy of CDK4/6 inhibitors, advances in immune checkpoint inhibitors, and the management of adverse reactions in precision oncology. As a clinical trial coordinator, she contributes to groundbreaking studies in targeted therapies and immuno-oncology. 🔬 Her expertise extends to translational oncology, aiming to bridge the gap between laboratory discoveries and real-world applications. By integrating clinical practice with research, she strives to improve patient survival and quality of life. 🏥🩺📊
Awards & Honors
🏆 Invited Speaker – National and International Oncology Conferences 🎤
🏆 Study Coordinator – AMGEN 20230016 Clinical Trial 🧪
🏆 Lecturer – Clinical Oncology Workshops & Summits 📚
🏆 Member – ESMO, ASCO, SNOMR, SRROM, and ROSPEN 🌍
🏆 Scientific Contribution – Published research on precision medicine and immunotherapy 🔬
🏆 Supervisor – 16 Bachelor’s Theses on oncology-related topics 🎓
Publication Top Notes:
📌 The prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma – 📝 Current Oncology 🔢 Cited by: 12
📌 An overview of the safety profile and clinical impact of CDK4/6 inhibitors in breast cancer—a systematic review of randomized phase II and III clinical trials – 📝 Biomolecules 🔢 Cited by: 9
📌 Metastatic kidney cancer: does the location of the metastases matter? Moving towards personalized therapy for metastatic renal cell carcinoma – 📝 Biomedicines 🔢 Cited by: 4
📌 Tumor-to-tumor metastasis of lung cancer to kidney cancer: a review of the literature and our experience – 📝 Diagnostics 🔢 Cited by: 4
📌 Second-line treatment of metastatic renal cell carcinoma in the era of predictive biomarkers – 📝 Diagnostics 🔢 Cited by: 3